Study of teduglutide effectiveness in parenteral nutrition-dependent short-bowel syndrome subjects

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 8, 2013, Pages 683-687

  Vipperla, Kishore ^a   O'Keefe, Stephen J ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

gattex; glucagon like peptide 2; intestinal failure; short bowel syndrome; teduglutide

Indexed keywords

PLACEBO; TEDUGLUTIDE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE CHOLECYSTITIS; ARTICLE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; NAUSEA; PARENTERAL NUTRITION; QUALITY OF LIFE; SHORT BOWEL SYNDROME; SMALL INTESTINE OBSTRUCTION; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL ABSORPTION; INTESTINE, SMALL; PARENTERAL NUTRITION; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHORT BOWEL SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 84887372677     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2013.842894     Document Type: Article

References (23)

1. O'Keefe SJ, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, Shaffer J. Short bowel syndrome and intestinal failure: Consensus definitions and overview. Clin. Gastroenterol. Hepatol. 4(1), 6-10 (2006).
2. Drozdowski L, Thomson AB. Intestinal mucosal adaptation. World J. Gastroenterol. 12(29), 4614-4627 (2006).
3. Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology 124(4), 1111-1134 (2003).
4. O'Keefe SJ, Haymond MW, Bennet WM, Oswald B, Nelson DK, Shorter RG. Long-Acting somatostatin analogue therapy and protein metabolism in patients with jejunostomies. Gastroenterology 107(2), 379-388 (1994).
5. Wales PW, Nasr A, De Silva N, Yamada J. Human growth hormone and glutamine for patients with short bowel syndrome. Cochrane Database Syst. Rev. 16(6)(2010).
6. Mullady DK, O'keefe SJ. Treatment of intestinal failure: Home parenteral nutrition. Nat. Clin. Pract. Gastroenterol. Hepatol. 3(9), 492-504 (2006).
7. Winkler MF, Hagan E, Wetle T, Smith C, Maillet JO, Touger-Decker R. An exploration of quality of life and the experience of living with home parenteral nutrition. JPEN J. Parenter. Enteral. Nutr. 34(4), 395-407 (2010).
8. O'Keefe SJ. Candidacy for intestinal transplantation. Am. J. Gastroenterol. 101(7), 1644-1646 (2006).
9. Thompson JS, Weseman R, Rochling FA, Mercer DF. Current management of the short bowel syndrome. Surg. Clin. North Am. 91(3), 493-510 (2011).
10. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122(2), 531-544 (2002).
11. Rowland KJ, Brubaker PL. The "cryptic" mechanism of action of glucagon-like peptide-2. Am. J. Physiol. Gastrointest. Liver Physiol. 301(1), 28 (2011).
12. Jeppesen PB, Hartmann B, Thulesen J et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 120(4), 806-815 (2001).
13. Bremholm L, Hornum M, Andersen UB, Hartmann B, Holst JJ, Jeppesen PB. The effect of Glucagon-Like P eptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regul. Pept. 168(1-3), 32-38 (2011).
14. Wojdemann M, Wettergren A, Hartmann B, Hilsted L, Holst JJ. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J. Clin. Endocrinol. Metab. 84(7), 2513-2517 (1999).
15. Drucker DJ, Shi Q, Crivici A et al. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat. Biotechnol. 15(7), 673-677 (1997).
16. Dacambra MP, Yusta B, Sumner-Smith M, Crivici A, Drucker DJ, Brubaker PL. Structural determinants for activity of glucagon-like peptide-2. Biochemistry 39(30), 8888-8894 (2000).
17. Marier JF, Beliveau M, Mouksassi MS et al. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J. Clin. Pharmacol. 48(11), 1289-1299 (2008).
18. Jeppesen PB, Sanguinetti EL, Buchman A et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 54(9), 1224-1231 (2005).
19. Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 60(7), 902-914 (2011).
20. O'Keefe SJ, Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B. Safety and Efficacy of Teduglutide After 52 Weeks of Treatment in Patients With Short Bowel Intestinal Failure. Clin. Gastroenterol. Hepatol. 17(13), 00087-00086 (2013).
21. Jeppesen PB, Pertkiewicz M, Messing B et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology 143(6), 1473-1481 (2012).
22. Crenn P, Messing B, Cynober L. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction. Clin. Nutr. 27(3), 328-339 (2008).
23. Thulesen J, Hartmann B, Hare KJ et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 53(8), 1145-1150 (2004).